Drug intelligence / Profile preview

Jiangbai Weiyan Tablets

Development stage: Unknown
Lead developer: Hangzhou Huadong Medicine Group New Drug Research Institute
Administration: Oral

Overview

Jiangbai Weiyan Tablets is a Traditional Chinese Medicine (TCM) product developed by Hangzhou Huadong Medicine Group Bioengineering Research Institute. It is primarily indicated for the treatment of chronic non-atrophic gastritis, specifically targeting the 'cold stagnation and qi stagnation' pattern in TCM. The formulation is designed to alleviate symptoms such as gastric pain and bloating by regulating qi and warming the stomach. It has undergone Phase II clinical evaluation in China to determine its safety and therapeutic efficacy compared to placebo.

Other names: Jiangbai Weiyan Pian

Beyond the preview

Go deeper on Jiangbai Weiyan Tablets.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiangbai Weiyan Tablets.

Explore the full profile